A multinational, multicenter, single visit, exploratory pharmacogenetic trial and long-term follow-up of the PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) trial
Completed
- Conditions
- Multiple Sclerose (MS)10007951
- Registration Number
- NL-OMON34946
- Lead Sponsor
- Merck Serono The Netherlands - a division of Merck B.V.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 16
Inclusion Criteria
Randomization in the PRISMS study
Exclusion Criteria
Unwilling or unable to participate in the study.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>* Genetic markers<br /><br>* BAbs/NAbs </p><br>
- Secondary Outcome Measures
Name Time Method <p>NAP</p><br>